Sacrococcygeal teratoma
| Sacrococcygeal teratoma | |
|---|---|
| Synonyms | SCT |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Mass at the base of the tailbone, constipation, urinary retention |
| Complications | Malignancy, hemorrhage, hydrops fetalis |
| Onset | Prenatal |
| Duration | Varies |
| Types | Type I, Type II, Type III, Type IV |
| Causes | Germ cell tumor |
| Risks | Female sex, twin pregnancy |
| Diagnosis | Ultrasound, MRI, CT scan |
| Differential diagnosis | Myelomeningocele, neuroblastoma, sacral agenesis |
| Prevention | None |
| Treatment | Surgical resection |
| Medication | Chemotherapy (if malignant) |
| Prognosis | Generally good if benign |
| Frequency | 1 in 35,000 to 40,000 live births |
| Deaths | N/A |
Sacrococcygeal teratoma (SCT) is a type of tumor that develops at the base of the coccyx (tailbone) of a newborn. It is a rare congenital disorder, occurring in approximately 1 in 40,000 live births. SCTs can be benign or malignant, and are more common in females than in males.
Signs and Symptoms[edit]
The most common sign of a sacrococcygeal teratoma is a mass that can be felt or seen on the newborn's lower back. Other symptoms may include constipation, urinary retention, and, in severe cases, respiratory distress due to the size of the tumor.
Causes[edit]
The exact cause of sacrococcygeal teratoma is unknown. However, it is believed to originate from pluripotent stem cells in the Hensen's node area during embryonic development.
Diagnosis[edit]
Diagnosis of SCT is often made prenatally through ultrasound imaging. Postnatal diagnosis is made through physical examination and imaging studies such as MRI or CT scan.
Treatment[edit]
Treatment for SCT typically involves surgical removal of the tumor. In some cases, chemotherapy may be required if the tumor is malignant.
Prognosis[edit]
The prognosis for SCT largely depends on the type and size of the tumor, as well as the presence of any complications. With early detection and treatment, the prognosis is generally good.
See Also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


